Athersys (ATHX) Stock Price
Athersys Price
Revenue at Athersys has contracted by 17.6% per year over the past 19 years to 80,000.00 USD. For Athersys, the net margin of -46,883.8% is down versus -808.1% a few years ago. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.
Athersys stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Athersys over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Athersys stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Athersys's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Athersys Price |
|---|
Athersys Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Athersys Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.01 | 0.01 | – | – | 0.01 | 0.02 | – | 0.02 | 0.01 | – | 0.01 | 0.01 | – | – | 0.02 | 2.77 |
| 25.00 | -30.00 | – | – | – | 60.00 | -87.50 | 1,050.00 | -78.26 | -80.00 | 400.00 | – | – | – | – | 13,095.24 |
| 100.00 | 114.29 | – | – | 110.00 | 100.00 | 100.00 | 104.35 | 100.00 | 100.00 | 100.00 | 100.00 | – | – | 100.00 | 100.00 |
| 0.01 | 0.01 | – | – | 0.01 | 0.02 | – | 0.02 | 0.01 | – | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 2.77 |
| -13.00 | -16.00 | -24.00 | -29.00 | -17.00 | -15.00 | -33.00 | -25.00 | -45.00 | -78.00 | -87.00 | -77.00 | -41.00 | -26.00 | -21.00 | -84.00 |
| -130.00 | -228.57 | – | – | -170.00 | -93.75 | -1,650.00 | -108.70 | -900.00 | -7,800.00 | -1,740.00 | -1,540.00 | – | – | -100.00 | -3.03 |
| -13.00 | -14.00 | -30.00 | -22.00 | -16.00 | -15.00 | -32.00 | -24.00 | -44.00 | -78.00 | -86.00 | -68.00 | -37.00 | – | -43.00 | -38.00 |
| 18.18 | 7.69 | 114.29 | -26.67 | -27.27 | -6.25 | 113.33 | -25.00 | 83.33 | 77.27 | 10.26 | -20.93 | -45.59 | – | – | -11.63 |
| 1.02 | 1.81 | 3.03 | 3.10 | 3.34 | 3.46 | 4.78 | 5.69 | 6.30 | 7.93 | 9.48 | 17.99 | 24.49 | 24.49 | 24.49 | 24.49 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Athersys generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Athersys retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Athersys's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Athersys has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Athersys's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Athersys stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Athersys Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Athersys business model & stock analysis
Athersys SWOT Analysis
Strengths
Athersys Inc has several key strengths that contribute to its overall competitiveness in the market. These strengths include:
- Talented and experienced executive team leading the organization.
- Strong intellectual property portfolio with innovative technologies.
- Robust research and development capabilities, driving continuous innovation.
- Healthy financial position with stable revenue streams.
- Established partnerships with leading industry players.
Weaknesses
Despite its strengths, Athersys Inc also faces certain weaknesses and challenges that can affect its performance. These weaknesses include:
- Relatively small market share compared to larger competitors.
- Dependence on key partners for distribution and commercialization.
- Highly regulated industry subject to strict compliance requirements.
- Limited marketing and brand awareness.
- Research and development costs can be substantial.
Opportunities
Athersys Inc can capitalize on various opportunities in the market to further grow and expand its business. These opportunities include:
- Increasing demand for regenerative medicine and cell therapy products.
- Emerging markets with unmet medical needs.
- Potential for strategic partnerships to enhance product development and commercialization.
- Advancements in technology, providing new avenues for innovation.
- Potential for mergers and acquisitions within the industry.
Threats
Athersys Inc operates in a competitive and dynamic market, facing various threats that can impact its success. These threats include:
- Intense competition from established and emerging biotechnology companies.
- Regulatory changes and uncertainties affecting product approvals and market access.
- Potential legal and intellectual property disputes.
- Technological advancements by competitors, potentially rendering Athersys Inc's products obsolete.
- Fluctuating market conditions and economic uncertainties.
Athersys Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Athersys Segments
Athersys Revenue by Segment (1/2)
3 Years
5 Years
Max
Details
Athersys Revenue by Segment (2/2)
3 Years
Max
Details
Athersys Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Athersys historical P/E ratio, EBIT multiple, and P/S ratio
Athersys annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Athersys shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Athersys stock splits
Current Athersys forecasts and price targets in August 2026
Analyst Price Targets 2026Athersys Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 3/6/2023 | Maintained | Buy | – | |
| 5/23/2022 | Downgrade | NeutralUnderperform | 70 | |
| 3/16/2022 | Maintained | Neutral | 70 | |
| 11/19/2021 | Downgrade | BuyNeutral | 70 | |
| 6/25/2020 | Maintained | Buy | 70 | |
| 5/8/2020 | Maintained | Buy | 70 | |
| 8/26/2019 | Maintained | Buy | – | |
| 3/28/2017 | Maintained | Outperform | – | |
| 2/7/2017 | Maintained | Buy | 70 | |
| 7/9/2015 | Downgrade | OverweightNeutral | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Athersys Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 5/16/2024 | -0.20USD | - | -USD | - | 2024 Q1 |
| 3/29/2024 | -0.20USD | - | 0.00USD | - | 2023 Q4 |
| 8/9/2023 | -0.09USD | - | 5.81 MUSD | - | 2023 Q2 |
| 5/4/2023 | -0.11USD | - | 126,874.00USD | - | 2023 Q1 |
| 3/13/2023 | -2.08USD | - | 0.00USD | - | 2022 Q4 |
| 11/14/2022 | -2.00USD | - | 0.00USD | - | 2022 Q3 |
| 8/11/2022 | -1.79USD | - | 0.00USD | - | 2022 Q2 |
| 5/6/2022 | -2.47USD | - | 697,812.00USD | - | 2022 Q1 |
| 3/15/2022 | -1.91USD | - | 42,295.00USD | - | 2021 Q4 |
| 11/15/2021 | -0.09USD | - | 42,295.00USD | - | 2021 Q3 |
Athersys shareholder structure
| % | Name |
|---|---|
3.14809% | |
1.52225% | |
0.72896% | |
0.64322% | |
0.35559% | |
0.25162% |
Athersys Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
9.96% | SEC ↗ | |
8.40% | SEC ↗ | |
8.40% | SEC ↗ | |
8.30% | SEC ↗ | |
8.30% | SEC ↗ | |
8.30% | SEC ↗ | |
8.30% | SEC ↗ | |
7.10% | SEC ↗ | |
7.10% | SEC ↗ | |
7.10% | SEC ↗ |
Frequently asked questions about Athersys
The business model of Athersys Inc is focused on the development and commercialization of novel regenerative medicine therapies. As a biotechnology company, Athersys is dedicated to leveraging its proprietary MultiStem® cell therapy platform to treat a range of medical conditions. The company collaborates with strategic partners in both commercial and clinical settings to advance its therapies and expand their potential applications. Athersys aims to address significant unmet medical needs and deliver effective, safe, and cost-efficient treatments for conditions such as stroke, acute respiratory distress syndrome (ARDS), and others. Through innovative research and partnerships, Athersys Inc strives to make a positive impact on patients' lives worldwide.
Athersys Inc is primarily active in the biotechnology industry.
The main competitors of Athersys Inc in the market include companies like Mesoblast Limited, Pluristem Therapeutics Inc, and ReNeuron Group plc. These competitors operate in the field of cell therapy and regenerative medicine, similar to Athersys Inc. Each of these companies aims to provide innovative solutions for treating various medical conditions through the use of stem cells and other advanced technologies.
Athersys Inc has a notable history and background in the biotechnology industry. The company, based in Cleveland, Ohio, was founded in 1995 by Dr. Gil Van Bokkelen. Athersys is focused on developing innovative regenerative therapies utilizing its proprietary stem cell technology platform called MultiStem®. Their research and development efforts have paved the way for potential treatments in various areas, including neurological disorders, inflammatory diseases, and cardiovascular conditions. Athersys has collaborated with leading pharmaceutical companies and academic institutions to advance their therapeutic programs. The company's commitment to pioneering regenerative medicine has positioned Athersys as a key player in the healthcare sector.
Athersys Inc, a leading biotechnology company, has achieved several significant milestones. Notably, they successfully completed Phase 2 clinical trials for their MultiStem® cell therapy in patients with ischemic stroke, demonstrating promising results in terms of safety and efficacy. Moreover, Athersys Inc received Fast Track designation from the FDA for the treatment of acute respiratory distress syndrome (ARDS), reflecting the potential impact of their therapy. Their collaborations with renowned institutions and organizations signify strong partnerships and commitment to advancing regenerative medicine. With continuous innovation and dedication, Athersys Inc is poised to make further strides in developing groundbreaking therapies for various unmet medical needs.
Athersys Inc is primarily present in the United States, focusing on developing their innovative regenerative medicine technologies.
Athersys Inc is committed to delivering innovative therapies that improve patients' lives. The company's corporate philosophy revolves around pioneering stem cell research and developing cutting-edge regenerative medicine technologies. Athersys Inc places immense value on scientific excellence and has a strong focus on collaboration and partnerships to drive advancements in healthcare. By leveraging its proprietary MultiStem® cell therapy platform, Athersys Inc aims to address critical medical needs and provide novel treatment options for conditions such as stroke, acute respiratory distress syndrome (ARDS), and other inflammatory and immune conditions. Through its dedication to scientific expertise and patient-centered approach, Athersys Inc strives to contribute to the betterment of healthcare worldwide.
7 analysts currently rate the Athersys stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Athersys to generate revenue of 2.77 B USD and earnings per share of -1.56 USD.
The Athersys share (ATHX) is listed on 5 stock exchanges, including: NASDAQ (ATHX), Frankfurt (4LS.F), München (4LS.MU), Düsseldorf (4LS.DU), SIX (Zürich) (4LS.SW).
Athersys Inc is a biotechnology company focused on developing and commercializing novel therapies for the treatment of diseases. The company is headquartered in Cleveland, Ohio and has subsidiaries in Europe and Asia. Athersys' business model includes three main divisions: regenerative medicine, clinical development, and commercialization. The company has developed a unique technology platform called MultiStem®, which is based on mesenchymal stem cells and has the ability to regulate inflammatory and regenerative processes in the body. The MultiStem technology is currently being studied in clinical trials for the treatment of various indications such as stroke, acute lung injuries, sepsis, and cancer. In the regenerative medicine division, Athersys collaborates closely with research institutions and industry partners to develop new applications for the MultiStem technology. The company has extensive experience in the manufacturing and characterization of mesenchymal stem cells and aims to develop the next generation of cell therapies. Athersys' clinical development division focuses on conducting clinical trials to evaluate the efficacy and safety of MultiStem in various diseases. The company works closely with regulatory authorities such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to obtain approval for MultiStem for the treatment of specific diseases. Finally, Athersys' commercialization division aims to establish MultiStem as an approved drug in the market. Through strategic partnerships with pharmaceutical manufacturers and other companies, the company aims to market MultiStem in different geographic regions and indications. Athersys currently does not have its own product on the market. However, the company collaborates with several pharmaceutical manufacturers and partners to advance the commercialization of MultiStem. Some of Athersys' partners include Pfizer, Healios, Nikon, Chugai, and Helios. In summary, Athersys' business model focuses on using the MultiStem technology for the development of cell-based therapies in regenerative medicine. The company is focused on conducting clinical trials to evaluate the efficacy and safety of MultiStem in the treatment of various diseases. Ultimately, Athersys aims to commercialize MultiStem through partnerships with a wide range of companies and the expansion into different geographic regions.
The expected revenue of Athersys is 2.77 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Athersys is -38.12 M USD. The net profit reflects the company's profitability after deducting all expenses.
The P/E ratio cannot be calculated for Athersys at the moment.
The P/S cannot be calculated for Athersys currently.
The Eulerpool Quality Score for Athersys is 2/10.
The ISIN of Athersys is US04744L1061. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Athersys is A0M085. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Athersys is ATHX. The ticker symbol is used to trade Athersys shares on the stock exchange.
Athersys is assigned to the 'Health' sector.
The dividends of Athersys are distributed in USD.
Athersys stock
Athersys Peer Group
Athersys Ticker
Athersys FIGI
All fundamentals and in-depth analysis of Athersys
Our stock analysis for Athersys stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Athersys. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.